Back to Home
Tech
21 Juni 2026
1

Nobel Laureate John Jumper Departs DeepMind for Anthropic in Major AI Talent Shift

John Jumper's move from Google DeepMind to Anthropic is a significant indicator of the escalating AI talent war and the strategic direction of leading AI companies. It underscores Anthropic's ambition to become a dominant force in AI for scientific discovery, particularly in the life sciences. This shift could accelerate breakthroughs in critical areas like drug discovery and disease understanding, while also posing a challenge to established tech giants in retaining their top research minds.

By NeuraFeed

Nobel Laureate John Jumper Departs DeepMind for Anthropic in Major AI Talent Shift

Nobel laureate John Jumper, a pivotal figure in the development of DeepMind's AlphaFold, has announced his departure from Google DeepMind to join rival AI startup Anthropic. This move intensifies the ongoing competition for top AI talent across the industry, following closely on the heels of other high-profile exits from Google's AI division. Jumper's transition signals Anthropic's aggressive push into the intersection of AI and fundamental science, particularly in computational biology and life sciences.

A Nobel-Winning Departure Rocks Google DeepMind

John Jumper, the Nobel Prize-winning scientist renowned for leading the development of AlphaFold, is leaving Google DeepMind after nearly nine years to join the AI startup Anthropic. This significant move, announced by Jumper on X, comes just days after Noam Shazeer, a co-lead of Google's Gemini AI models, also departed Google for OpenAI, marking a substantial loss of top-tier talent for Google's AI operations within a 48-hour period.

Jumper, who shared the 2024 Nobel Prize in Chemistry with DeepMind CEO Demis Hassabis for their work on AlphaFold, is recognized as one of the most respected scientists in artificial intelligence and computational biology. His groundbreaking work with AlphaFold, an AI system that predicts the three-dimensional structure of proteins from their amino acid sequences, has been hailed as one of the most important AI breakthroughs in biology and medical research. AlphaFold has been utilized by over two million scientists across 190 countries, accelerating research in areas such as malaria vaccines, cancer treatments, and drug-resistant bacteria.

Anthropic's Strategic Play in AI for Science

Jumper's decision to join Anthropic underscores the startup's aggressive strategy in recruiting leading AI researchers and expanding its focus on AI for science. While his specific role at Anthropic has not yet been disclosed, the hire aligns with Anthropic's growing investment in life sciences and computational biology. Anthropic has been actively building dedicated AI-for-science infrastructure throughout 2026, including establishing wet labs and forging partnerships with institutions like the Allen Institute and Howard Hughes Medical Institute.

In April, Anthropic further solidified its commitment to this domain by acquiring Coefficient Bio, a stealth biotech startup specializing in protein design and biomolecule modeling. This acquisition, coupled with Jumper's expertise, provides Anthropic with considerable scientific credibility as it aims for a "meaningful percentage of all of the life science work in the world to run on Claude," its flagship AI model. Jumper's move signals that the frontier of AI is shifting towards systems that can engage in consequential scientific work, moving beyond just conversational models.

The Intensifying AI Talent War

The departure of a Nobel laureate like Jumper highlights the intense competition for top AI talent across the industry, with startups like Anthropic and OpenAI aggressively vying with tech giants such as Google and Meta. This talent drain from Google DeepMind, particularly the back-to-back exits of Jumper and Shazeer, raises questions about Google's ability to retain its most celebrated researchers, even with substantial compensation packages.

Industry analysts suggest that leaner organizations like Anthropic and OpenAI may offer less bureaucracy and a more singular focus on achieving superintelligence, which can be highly attractive to elite researchers. Demis Hassabis, CEO of Google DeepMind, publicly acknowledged Jumper's contributions, stating that AlphaFold "changed the world, and showed the field what was possible with AI for science and medicine, lighting the way for how AI can benefit humanity." Despite these high-profile departures, Google DeepMind remains a formidable research operation, with its Gemini models powering products used by millions and its spin-off Isomorphic Labs pursuing AI-designed drug candidates in clinical trials.